← Leaderboards

Robert S Bresalier

Henry Ford Health System

Google Scholar ↗PubMed ↗ORCID ↗

$7,222,680

Attributed

$10,985,930

Total exposure

6

Grants

4

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2006–25

$2M$1.5M$1M$500K$0

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$10,985,930 · 6

By mechanism

U01$6,607,334 · 3

R01$4,378,596 · 3

Top collaborators

Most similar at Henry Ford Health System

Same institution · by research overlap

Shulin Li$17,068,216

Others in their field

Top investigators on “Proteins”

David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
Randall J Bateman · Washington University$187,292,085
Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
Reisa A. Sperling · Banner Health$145,046,481
Barton F Haynes · Duke University$136,029,850
Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280

Research focus

ProteinsValidationTissuesIncidenceSpecimenColon CarcinomaModalityMalignant NeoplasmsColorectal CancerSiteGene ExpressionUnited StatesBloodSamplingPerformanceProspectiveEarly DiagnosisScreeningBinding ProteinsMucinsGlycoproteinsResponseLinkCessation Of Life

Grant awards (23)

Multi-cancer early detection using cell-free DNA methylome analysis$925,584

U01 · FY2025 · CA

Great Lakes New England Clinical Validation Center$966,077

U01 · FY2024 · CA · contact PI

Multi-cancer early detection using cell-free DNA methylome analysis$879,305

U01 · FY2024 · CA

Great Lakes New England Clinical Validation Center$1,016,923

U01 · FY2023 · CA · contact PI

Multi-cancer early detection using cell-free DNA methylome analysis$952,611

U01 · FY2023 · CA

Great Lakes New England Clinical Validation Center$803,955

U01 · FY2022 · CA · contact PI

Integrated Signaling in Pancreatic Cancer Progression$366,000

R01 · FY2021 · CA · contact PI

Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype$222,027

U01 · FY2021 · CA

Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype$392,221

U01 · FY2020 · CA

Integrated Signaling in Pancreatic Cancer Progression$366,000

R01 · FY2020 · CA · contact PI

Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype$448,631

U01 · FY2019 · CA

Integrated Signaling in Pancreatic Cancer Progression$355,019

R01 · FY2019 · CA · contact PI

Integrated Signaling in Pancreatic Cancer Progression$366,000

R01 · FY2017 · CA · contact PI

Molecular Mediators of Pancreatic Cancer Invasion and Progression$332,000

R01 · FY2017 · CA · contact PI

Mucin Glycoproteins in Colon Cancer Metastasis$304,035

R01 · FY2010 · CA · contact PI

Mucin Glycoproteins in Colon Cancer Metastasis$304,035

R01 · FY2009 · CA · contact PI

Mucin Glycoproteins in Colon Cancer Metastasis$304,035

R01 · FY2008 · CA · contact PI

Mucin Glycoproteins in Colon Cancer Metastasis$304,035

R01 · FY2007 · CA · contact PI

Mucin Glycoproteins in Colon Cancer Metastasis$326,615

R01 · FY2006 · CA · contact PI

MUCIN GLYCOPROTEINS IN COLON CANCER METASTASIS$350,000

R01 · FY2002 · CA

MUCIN GLYCOPROTEINS IN COLON CANCER METASTASIS$7,440

R01 · FY2002 · CA

MUCIN GLYCOPROTEINS IN COLON CANCER METASTASIS$350,239

R01 · FY2001 · CA

MUCIN GLYCOPROTEINS IN COLON CANCER METASTASIS$343,143

R01 · FY2000 · CA